NCT07652294 Phase 2 Enrolling by invitation
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD Study sponsor: Spyre Therapeutics, Inc. · SYRE
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Changes Study details Primary completion 2029-03-02 Estimated
Enrollment · participants 645 Estimated
Source updated 2026-09-15 Last update listed in the registry record
Version history
Changes to this trial Last 12 months Posted 2026-06-18 · 1 field changed
Primary outcomes · main study measures Text edit · unverified significance − Previous value measure: To assess the safety and tolerability of study drug treatment regimens
+ Updated value measure: Percentage of participants who experienced an adverse event
The saved outcome text may be shortened. Check the source for full wording.
Check registry source This database covers selected trials and recorded edits. Some past edits may be missing, and saved text about the main study measures (endpoints) may be shortened. Check the original registry record when a detail matters. Read our methodology
Trial